• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

    5/2/22 7:00:00 AM ET
    $EVFM
    $OBSV
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVFM alert in real time by email

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

    GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth transition, Dr. Garner has agreed to provide advisory consulting services to ObsEva on an as needed basis.

    "We are pleased to welcome Brandi, a recognized expert in women's health, at this promising time for ObsEva as we anticipate our first product approvals in 2022 and further advancement of our attractive pipeline," said Brian O'Callaghan, CEO of ObsEva. "Brandi is the clear and unanimous choice of the Board and executive team to serve as our Chief Clinical Officer, given her demonstrated success leading clinical development programs, medical affairs organizations, new product launches, and regulatory processes. We wish Beth well in her future endeavors. I know I speak on behalf of all our employees when I say that it has been an honor and pleasure to work together, and I am very pleased that Beth will remain a key part of ObsEva's future success as an advisor to the Company."

    Dr. Howard has deep women's health expertise with increasing responsibilities in medical affairs strategy and leadership, as well as leading large clinical development programs. She was previously Head of Medical and Clinical Affairs at Evofem Biosciences (NASDAQ:EVFM) since 2016 where she led the clinical program for the FDA approval of Phexxi®, as well as the creation of the medical affairs organization in support of the launch. Dr. Howard was also responsible for driving the successful Phase 2b/3 study for additional indications and the current Phase 3 confirmatory trial. Prior to joining Evofem, she spent eight years in various roles at Teva Pharmaceuticals (NYSE:TEVA) in Global and U.S. medical affairs, including as Head of U.S. Field Medical Affairs directing over 100 medical affairs professionals across eight therapeutic areas and the U.S. Medical Director for Women's Health. Dr. Howard has also been actively involved in investor relations and business development activities in prior roles. Her Ph.D. research at the University of Pennsylvania focused on adolescent sexual behaviors and contraceptive use. She earned her Bachelor of Science, Nursing, from the Medical College of Georgia and her Master of Science, Women's Health and Perinatology, from Georgia State University.

    Dr. Howard commented: "It's an exciting time to be joining ObsEva, with the expected approval of linzagolix for uterine fibroids in Europe and the United States in the next six months and subsequent transition to a commercial-stage company. With a talented team and promising pipeline in place, ObsEva is strongly positioned to address the most challenging unmet needs facing women and bring much needed innovation to the field. I look forward to building on the momentum created by Beth and the team to date, and being part of ObsEva's next phase of growth."

    Dr. Garner added: "It has been a privilege to work with the remarkably talented and driven team at ObsEva. Brandi and I have had a close professional relationship for a number of years, and I believe she is ideally suited to lead the clinical development and medical affairs strategy at ObsEva going forward. I look forward to contributing to the Company's ongoing achievements in my capacity as a consultant and am confident of ObsEva's future success."



    About ObsEva

    ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's health. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is traded under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.

    Cautionary Note Regarding Forward-Looking Statements

    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "ongoing", "objective", "plan", "potential", "predict", "should", "will", "would", or the negative of these and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the potential approval of linzagolix by regulatory authorities, including the European Commission and the U.S. Food and Drug Administration (FDA), and the timing of such approval and subsequent transition of ObsEva to a commercial-stage company, the timing or results of interactions with regulatory authorities, clinical development of ObsEva's product candidates, including the timing, advancement of, and potential therapeutic benefits of such product candidates, including linzagolix, the potential for linzagolix and other product candidates to be commercially competitive, the success of the Company's partnerships with third parties, expectations regarding regulatory and development milestones and ObsEva's ability to obtain and maintain regulatory approvals for its product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, including interactions with the European Medicines Agency during the marketing authorization application process and with the FDA during the New Drug Application process for linzagolix, ObsEva's reliance on third parties over which it may not always have full control, and the capabilities of such third parties, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva's website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.



    For further information, please contact:

    CEO Office contact

    Shauna Dillon

    [email protected]

    +41 22 552 1550

    Investor Contact

    Katja Bührer

    [email protected]

    +1 (917) 969-3438





     

    Attachment

    • Press Release in Pdf


    Primary Logo

    Get the next $EVFM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EVFM
    $OBSV
    $TEVA

    CompanyDatePrice TargetRatingAnalyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    6/6/2025$24.00Buy
    Goldman
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/28/2025$25.00Buy
    Truist
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/12/2025$23.00Neutral → Overweight
    Analyst
    Teva Pharmaceutical Industries Limited
    $TEVA
    7/10/2024$20.00Hold → Buy
    Argus
    Teva Pharmaceutical Industries Limited
    $TEVA
    3/8/2024$14.00Underweight → Neutral
    JP Morgan
    Teva Pharmaceutical Industries Limited
    $TEVA
    2/12/2024$12.00 → $19.00Neutral → Overweight
    Piper Sandler
    Teva Pharmaceutical Industries Limited
    $TEVA
    1/23/2024$10.00 → $14.00Hold → Buy
    Jefferies
    Teva Pharmaceutical Industries Limited
    $TEVA
    1/3/2024$8.00 → $12.00Underweight → Neutral
    Piper Sandler
    More analyst ratings

    $EVFM
    $OBSV
    $TEVA
    SEC Filings

    See more
    • Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

      7/2/25 4:14:07 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Evofem Biosciences Inc.

      D - Evofem Biosciences, Inc. (0001618835) (Filer)

      7/2/25 3:13:43 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Teva Pharmaceutical Industries Limited

      8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)

      6/5/25 4:52:32 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    $OBSV
    $TEVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Teva Pharma with a new price target

      Goldman initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $24.00

      6/6/25 8:33:51 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist initiated coverage on Teva Pharma with a new price target

      Truist initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $25.00

      5/28/25 9:09:46 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Pharma upgraded by Analyst with a new price target

      Analyst upgraded Teva Pharma from Neutral to Overweight and set a new price target of $23.00

      5/12/25 8:18:58 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    $OBSV
    $TEVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teva Releases Q2 2025 Aide Memoire

      TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the "Investors" page on its website. Q2 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicine

      6/26/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

      TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h

      6/25/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    $OBSV
    $TEVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Financial Officer Kalif Eliyahu Sharon sold $952,464 worth of Ordinary Shares (55,775 units at $17.08), decreasing direct ownership by 12% to 403,288 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/16/25 4:03:30 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vergis Janet S. converted options into 9,632 units of Ordinary Shares, increasing direct ownership by 15% to 73,697 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/9/25 4:25:12 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Zaks Tal Zvi converted options into 9,632 units of Ordinary Shares, increasing direct ownership by 20% to 58,772 units (SEC Form 4)

      4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

      6/9/25 4:22:54 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    $OBSV
    $TEVA
    Leadership Updates

    Live Leadership Updates

    See more
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

      4/17/25 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

      Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

      10/29/24 8:15:00 AM ET
      $ADTX
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    $OBSV
    $TEVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

      SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      11/12/24 10:34:14 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

      SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

      4/9/24 10:26:26 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

      SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

      2/14/24 2:14:48 PM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVFM
    $OBSV
    $TEVA
    Financials

    Live finance-specific insights

    See more
    • Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

      TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be available within 24 h

      6/25/25 4:30:00 PM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

      SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the fourth qua

      5/15/25 7:59:00 AM ET
      $EVFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

      For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration.Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%.AUSTEDO® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion.AJOVY® – global revenues of $139 million

      5/7/25 7:00:00 AM ET
      $TEVA
      Biotechnology: Pharmaceutical Preparations
      Health Care